zimberelimab: Clinical Trials

45 trials of zimberelimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 active not recruiting, 11 recruiting, 6 completed, 5 not yet recruiting. 45 Phase 2, 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 245Active not recruiting 13, Recruiting 11, Completed 6, Not yet recruiting 5, Unknown 5, Terminated 2, Withdrawn 2, Suspended 1
Phase 17Recruiting 3, Completed 2, Suspended 1, Unknown 1

Follow zimberelimab: new trials by email Literature Review of zimberelimab trials Research Report on zimberelimab

Trials (filtered) newest first · largest first

All 45 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer
Becotatug Vedotin in combination with Zimberelimab - Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal Neoplasms
Phase 2RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology302026-06-112026-06-16
Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC
Zimberelimab (AB122), Domvanalimab (DOM), Sacituzumab Govitecan (SG) - Triple Negative Breast Cancer, PDL-1 Positive
Phase 2WithdrawnMedSIR2026-04-012026-05-01
Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)
FOLFIRI + Zimberelimab + Domvanalimab, FOLFIRI (standard of care) - Carcinoma, Neuroendocrine
Phase 2Not yet recruitingHospices Civils de Lyon1222026-04-012026-01-13
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Casdatifan, Zimberelimab - Renal Cell Carcinoma, Kidney Cancer
Phase 2RecruitingDana-Farber Cancer Institute322026-03-092026-03-20
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
Zimberelimab, Domvanalimab, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel) - Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction
Phase 2WithdrawnMassachusetts General Hospital2026-02-012025-12-26
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 - Peritoneal Mesothelioma, Gestational Trophoblastic Tumor
Phase 2Active not recruitingHospices Civils de Lyon272025-10-012026-06-25
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
Domvanalimab, Zimberelimab, Paclitaxel - Head and Neck Squamous Cell Carcinoma
Phase 2Active not recruitingGilead Sciences392025-02-182026-09-03
PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
Sacituzumab govitecan, Zimberelimab, Domvanalimab - Urothelial Bladder Carcinoma
Phase 2Active not recruitingFundación para el Progreso de la Oncología en Cantabria702025-01-202026-10-07
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
Stereotactic Radiation, Zimberelimab, Sacituzumab govitecan - Breast Cancer, Triple Negative Breast Cancer
Phase 1 / Phase 2RecruitingH. Lee Moffitt Cancer Center and Research Institute312024-12-192025-12-05
Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer
Sacituzumab Govitecan + Zimberelimab - Bladder Cancer, Bladder Urothelial Carcinoma
Phase 2Not yet recruitingFondazione IRCCS Istituto Nazionale dei Tumori, Milano632024-12-022024-07-30
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat - Pancreatic Ductal Adenocarcinoma
Phase 2RecruitingGulam Manji602024-05-102026-02-27
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Gemcitabine, Cisplatin, Zimberelimab - Biliary Tract Carcinoma, Cholangiocarcinoma
Phase 2Active not recruitingNataliya Uboha332024-03-082026-08-17
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
Disitamab Vedotin, Zimberelimab - Cervical Cancer
Phase 2RecruitingRemeGen Co., Ltd.1162024-01-112024-02-28
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
Zimberelimab, Oxaliplatin, S-1 - Previously AG Chemotherapy Treated Pancreatic Cancer
Phase 2Not yet recruitingShanghai Zhongshan Hospital192024-01-012023-12-12
Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma
Cetuximab, Zimberelimab, Docetaxel - Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable
Phase 2UnknownXuekui Liu522023-12-012023-11-22
Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.
Zimberelimab, Platinum, radiotherapy - Cervical Cancer
Phase 2Not yet recruitingObstetrics & Gynecology Hospital of Fudan University242023-12-012023-11-30
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
Zimberelimab, Albumin-bound Paclitaxel, Cisplatin - Locally Advanced Cervical Cancer
Phase 2RecruitingTang-Du Hospital202023-10-092023-09-28
SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)
Stereotactic body radiation(SBRT), Zimberelimab (GLS-010) - Locally Advanced Pancreatic Cancer
Phase 2Not yet recruitingPeking University Third Hospital962023-08-012023-08-24
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
Quemliclustat, Etrumadenant, Zimberelimab - Oligometastatic Prostate Cancer
Phase 2RecruitingCatherine Spina232023-07-012025-05-20
A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma
Zimberelimab 240mg - Classical Hodgkin Lymphoma
Phase 2UnknownSun Yat-sen University542023-06-142023-06-18

Showing 20 of 45. Sign in to see all of them.

Conditions studied

Uterine Cervical Neoplasms (6)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Lung Neoplasms (3)  ·  Squamous Cell Carcinoma of Head and Neck (3)  ·  Triple Negative Breast Neoplasms (3)  ·  Cholangiocarcinoma (2)  ·  Neoplasm Metastasis (2)  ·  Pancreatic Neoplasms (2)  ·  Stomach Neoplasms (2)  ·  Adenocarcinoma Of Esophagus (1)  ·  Bile Duct Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Carcinoid Tumor (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Neuroendocrine (1)

Sponsors

Arcus Biosciences, Inc. (5)  ·  Gilead Sciences (5)  ·  Guangzhou Gloria Biosciences Co., Ltd. (3)  ·  Sun Yat-sen University (3)  ·  Hospices Civils de Lyon (2)  ·  Catherine Spina (1)  ·  Coherus Oncology, Inc. (1)  ·  Dana-Farber Cancer Institute (1)  ·  Diwakar Davar (1)  ·  Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1)  ·  Fudan University (1)  ·  Fundación para el Progreso de la Oncología en Cantabria (1)  ·  Gulam Manji (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  James Cleary, MD, PhD (1)

Countries

United States (25)  ·  China (13)  ·  France (8)  ·  South Korea (7)  ·  Italy (6)  ·  Spain (6)  ·  United Kingdom (6)  ·  Taiwan (5)  ·  Australia (4)  ·  Canada (4)  ·  Hong Kong (4)  ·  Turkey (Türkiye) (3)  ·  Germany (2)  ·  Malaysia (2)  ·  Poland (2)

Top investigators

Catherine S. Spina, MD, PhD (1)  ·  Daniel Morgensztern, M.D. (1)  ·  David Hsieh, MD (1)  ·  Diwakar Davar, MD (1)  ·  Encouse Golden, M.D., Ph.D. (1)  ·  Giuseppe Procopio, MD (1)  ·  Guiling Li, Doctor (1)  ·  Gulam Manji, MD, PhD (1)  ·  Hongxi Zhao, PhD (1)  ·  Ignacio Duran, MD (1)  ·  James Cleary, MD, PhD (1)  ·  Jianmin Fang, Ph.D (1)  ·  Jun Zhu, MD (1)

Results publications

PMID 33929895, PMID 34462189, PMID 37875323, PMID 38261969, PMID 38682560, PMID 39186707, PMID 39799811, PMID 40592848, PMID 41109921, PMID 42481461

NIH funding

2023 (2), 2025 (1)